Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety, tolerability, PK, and PD of single and multiple ascending SC doses of CB4211 in healthy non obese subjects and subjects with NAFLD.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - CB4211 Dose 1

Administered by subcutaneous injection

Drug - CB4211 Dose 2

Administered by subcutaneous injection

Drug - CB4211 Dose 3

Administered by subcutaneous injection

Drug - CB4211 Dose 4

Administered by subcutaneous injection

Drug - CB4211 Dose 5

Administered by subcutaneous injection

Drug - CB4211 Dose 6

Administered by subcutaneous injection

Drug - CB4211 Dose TBD

Administered by subcutaneous injection

Drug - Placebo

Administered by subcutaneous injection

Additional Information

Official Study Title

A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

Clinical Trial ID

NCT03998514

ParticipAid ID

aADEle